Supplementary Table 5. Demographic data and baseline characteristics after propensity score matching in the patient subgroup with available health examination data

Characteristic	Cohort 1			Cohort 2		
	SGLT2i (*n*=9,205)	DPP-4i (*n*=9,205)	Standardized difference	SGLT2i (*n*=7,998)	SU (*n*=7,998)	Standardized difference
Age, yr	52.3±10.5	52.2±11.1	0.7	53.2±10.4	53.2±11.5	0.9
Women	3,890 (42.3)	3,867 (42.0)	0.5	3,271 (40.9)	3,196 (40.0)	1.9
Index year						
2014	816 (8.9)	804 (8.7)	0.5	788 (9.9)	796 (10.0)	0.3
2015	3,224 (35.0)	3,203 (34.8)	0.5	2,974 (37.2)	2,979 (37.2)	0.1
2016	5,165 (56.1)	5,198 (56.5)	0.7	4,236 (53.0)	4,223 (52.8)	0.3
Comorbidities						
Cardiovascular disease	1,723 (18.7)	1,736 (18.9)	0.4	1,442 (18.0)	1,396 (17.5)	1.5
Myocardial infarction	162 (1.8)	173 (1.9)	0.9	123 (1.5)	125 (1.6)	0.2
PCI with stent	102 (1.1)	116 (1.3)	1.4	68 (0.9)	58 (0.7)	1.4
Unstable angina	239 (2.6)	255 (2.8)	1.1	209 (2.6)	192 (2.4)	1.4
Angina pectoris	986 (10.7)	1,011 (11.0)	0.9	797 (10.0)	814 (10.2)	0.7
Heart failure	361 (3.9)	384 (4.2)	1.3	292 (3.7)	278 (3.5)	0.9
Atrial fibrillation	137 (1.5)	144 (1.6)	0.6	109 (1.4)	114 (1.4)	0.5
Stroke	521 (5.7)	546 (5.9)	1.2	465 (5.8)	453 (5.7)	0.6
Peripheral artery disease	6 (0.1)	8 (0.1)	0.8	4 (0.1)	5 (0.1)	0.5
Chronic kidney disease	64 (0.7)	83 (0.9)	2.3	50 (0.6)	52 (0.7)	0.3
Diabetic neuropathy	740 (8.0)	732 (8.0)	0.3	634 (7.9)	639 (8.0)	0.2
Diabetic retinopathy	1,156 (12.6)	1,162 (12.6)	0.2	957 (12.0)	939 (11.7)	0.7
Diabetic nephropathy	1,101 (12.0)	1,119 (12.2)	0.6	738 (9.2)	747 (9.3)	0.4
Severe hypoglycemia	105 (1.1)	108 (1.2)	0.3	90 (1.1)	76 (1.0)	1.7
Keto-/lactate acidosis	25 (0.3)	20 (0.2)	1.1	23 (0.3)	22 (0.3)	0.2
Cancer	711 (7.7)	735 (8.0)	1.0	584 (7.3)	626 (7.8)	2.0
Frailty (yes)	145 (1.6)	153 (1.7)	0.7	96 (1.2)	96 (1.2)	0.0
Drugs						
Low dose acetylic salicylic acid	1,457 (15.8)	1,461 (15.9)	0.1	1,281 (16.0)	1,276 (16.0)	0.2
Statin therapy	5,807 (63.1)	5,857 (63.6)	1.1	4,798 (60.0)	4,834 (60.4)	0.9
ACE inhibitors	162 (1.8)	159 (1.7)	0.2	140 (1.8)	138 (1.7)	0.2
ARB	3,709 (40.3)	3,738 (40.6)	0.6	3,120 (39.0)	3,101 (38.8)	0.5
Dihydropyridines	1,284 (13.9)	1,285 (14.0)	0.0	1,187 (14.8)	1,206(15.1)	0.7
Low ceiling diuretics	528 (5.7)	519 (5.6)	0.4	482 (6.0)	468 (5.9)	0.7
Beta blockers	1,161 (12.6)	1,171 (12.7)	0.3	971 (12.1)	936 (11.7)	1.4
Non-hydropyridines	193 (2.1)	210 (2.3)	1.3	150 (1.9)	160 (2.0)	0.9
High ceiling diuretics	209 (2.3)	208 (2.3)	0.1	181 (2.3)	156 (2.0)	2.2
Aldosterone antagonists	109 (1.2)	108 (1.2)	0.1	88 (1.1)	87 (1.1)	0.1
Warfarin	36 (0.4)	40 (0.4)	0.7	32 (0.4)	34 (0.4)	0.4
Receptor P2Y12 antagonists	450 (4.9)	491 (5.3)	2.0	362 (4.5)	372 (4.7)	0.6

(*Continued to the next page*)

Supplementary Table 5. Continued

Characteristic	Cohort 1			Cohort 2		
	SGLT2i (*n*=9,205)	DPP-4i (*n*=9,205)	Standardized difference	SGLT2i (*n*=7,998)	SU (*n*=7,998)	Standardized difference
Result of examination						
Body mass index, kg/m²	27.8±4.1	27.7±4.3	0.8	27.2±3.8	27.2±4.0	1.1
Waist circumference, cm	90.3±9.9	90.3±10.1	0.5	89.3±9.3	89.3±9.9	0.7
Systolic blood pressure, mm Hg	129.4±15.0	129.2±15.3	1.0	129.2±14.9	129.1±15.3	0.8
Diastolic blood pressure, mm Hg	80.7±10.3	80.7±10.4	0.4	80.5±10.2	80.4±10.4	1.2
Fasting glucose, mg/dL	161.6±53.8	162.3±52.9	1.4	164.5±55.3	165.0±58.0	0.8
Total cholesterol, mg/dL	205.2±51.0	205.4±58.0	0.4	206.2±51.5	206.4±47.1	0.4
HDL-C, mg/dL	49.5±12.5	49.5±12.6	0.1	49.7±12.4	49.5±12.8	1.8
LDL-C, mg/dL	117.5±48.5	117.5±54.9	0.1	118.4±49.5	118.7±47.4	0.6
Triglyceride, mg/dL	210.8±187.6	211.3±187.3	0.3	209.9±185.9	211.4±181.4	0.8
Creatinine, mg/dL	0.9±0.5	0.9±0.3	0.2	0.9±0.5	0.9±0.5	0.8
eGFR, mL/min/1.73 m²	93.0±24.4	93.0±24.6	0.1	92.5±24.6	92.8±25.4	1.3
Smoking status						
Non-smoker	4,911 (53.4)	4,861 (52.8)	1.1	4,167 (52.1)	4,140 (51.8)	0.7
Former smoker	1,927 (20.9)	1,955 (21.2)	0.7	1,705 (21.3)	1,740 (21.8)	1.1
Current smoker	2,367 (25.7)	2,389 (26.0)	0.5	2,126 (26.6)	2,118 (26.5)	0.2
Alcohol intake						
Abstinent	8,586 (93.3)	8,586 (93.3)	0.0	7,433 (92.9)	7,435 (93.0)	0.1
Low-medium	389 (4.2)	400 (4.3)	0.6	358 (4.5)	352 (4.4)	0.4
High	230 (2.5)	219 (2.4)	0.8	207 (2.6)	211 (2.6)	0.3
Physical activity						
Low	4,125 (44.8)	4,162 (45.2)	0.8	3,641 (45.5)	3,638 (45.5)	0.1
Medium	4,396 (47.8)	4,394 (47.7)	0.0	3,753 (46.9)	3,757 (47.0)	0.1
High	684 (7.4)	649 (7.1)	1.5	604 (7.6)	603 (7.5)	0.0

Values are presented as mean±standard deviation or number (%). Frailty was defined by at least one hospital admission of ≥3 consecutive days during preceding year before the index date.

SGLT2i, sodium glucose cotransporter 2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea; PCI, percutaneous coronary intervention; ACE, angiotensin converting enzyme; ARB angiotensin receptor blocker; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.